[8-K] Willis Lease Finance Corp Reports Material Event

Rhea-AI Filing Summary

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) filed a Form 8-K on 15 July 2025 to disclose a patent milestone for its commercial product Igalmi. The U.S. Patent & Trademark Office has allowed U.S. Patent Application No. 18/600,419, which covers administration of a single oromucosal dose of up to 120 mcg dexmedetomidine for treating acute agitation associated with schizophrenia or bipolar disorder in patients exhibiting a QT prolongation of <6 µs. Once issued, the patent will be eligible for Orange Book listing and will become the 14th Orange Book-listed patent for Igalmi. The patent carries an expiry date of 12 January 2043, subject to any patent-term adjustment. No financial metrics or other operational updates were included in this filing.

• Form type: 8-K – Item 8.01 (Other Events)
• Event date: 15 July 2025
• Key asset: Igalmi (dexmedetomidine oromucosal film)
• IP impact: additional Orange Book protection through 2043, strengthening the product’s U.S. exclusivity position

Insights

Securities Analyst

Newly allowed patent extends Igalmi exclusivity to 2043 and adds 14th Orange Book listing, a positive IP development despite lack of immediate financial metrics.

The allowance of Application 18/600,419 materially expands BioXcel’s intellectual-property shield around Igalmi. With an expiry in 2043, the company secures roughly 17.5 more years of statutory protection from the allowance date, which may deter generic challengers during that window. While the filing contains no sales or earnings data, patent additions of this length are typically viewed favorably by investors who value prolonged revenue visibility. Because this 8-K is focused solely on the IP event, the disclosure is impactful yet limited in scope, warranting a positive rating.

Intellectual Property Specialist

Orange Book eligibility of USPTO-allowed single-dose dexmedetomidine patent tightens Igalmi’s patent estate through 2043, complicating generic entry timelines.

The patent’s claims track the FDA-recommended dosing for Igalmi in a defined subpopulation, enhancing enforceability because they mirror the approved label. Orange Book listing provides an automatic notification framework—any ANDA filer must certify against this patent, triggering potential 30-month stays if contested. Becoming the 14th Orange Book patent, the estate now covers both formulation and method-of-use aspects, creating layered barriers. The 2043 expiry materially lengthens exclusivity relative to standard 20-year terms, signaling strong protection for the product’s commercial life cycle.

0001018164false00010181642025-07-152025-07-15

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________________________________________________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 ______________________________________________________________________

Date of Report (Date of earliest event reported): July 15, 2025

Willis Lease Finance Corporation

(Exact Name of Registrant as Specified in Charter)

Delaware

001-15369

68-0070656

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(I.R.S. Employer Identification Number)

4700 Lyons Technology Parkway

Coconut Creek, FL 33073

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (561) 349-9989

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol

Name of exchange on which registered

Common Stock, $0.01 par value per share

WLFC

Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 7.01 Regulation FD Disclosure.

On July 15, 2025, Willis Lease Finance Corporation (NASDAQ: WLFC) (the “Company”) issued a press release announcing that it plans to conduct a conference call on Tuesday, August 5, 2025, at 10:00 a.m. Eastern Time to discuss its financial results for the second quarter of 2025. The Company will report its financial results in a press release prior to the conference call.

A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K.

The foregoing information, including the press release attached hereto as Exhibit 99.1, is being furnished pursuant to Item 7.01 of this Current Report on Form 8-K and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements & Exhibits.

Exhibit No.						Description
99.1						News Release issued by Willis Lease Finance Corporation dated July 15, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned duly authorized officer.

Dated: July 15, 2025

			WILLIS LEASE FINANCE CORPORATION
			By:			/s/ Scott B. Flaherty
						Scott B. Flaherty
						Executive Vice President and Chief Financial Officer

3